Table 4

Adjusted likelihood for hospitalised patients with different haematological malignancies to receive specific treatments during the last month before death

ChemotherapyBlood transfusionInvasive ventilationHaemodynamic support
Adjusted OR (95% CI)*Adjusted OR (95% CI)*Adjusted OR (95% CI)*Adjusted OR (95% CI)*
Acute leukaemia1111
Chronic lymphoid leukaemia0.57 (0.51 to 0.63)0.30 (0.28 to 0.33)1.81 (1.62 to 2.03)1.70 (1.53 to 1.90)
Chronic myeloid leukaemia0.28 (0.22 to 0.34)0.48 (0.42 to 0.54)1.97 (1.63 to 2.36)1.99 (1.68 to 2.36)
Hodgkin’s disease1.04 (0.90 to 1.21)0.28 (0.25 to 0.32)1.93 (1.64 to 2.28)1.99 (1.69 to 2.33)
Multiple myeloma1.19 (1.12 to 1.27)0.38 (0.36 to 0.40)0.96 (0.87 to 1.05)1.03 (0.94 to 1.12)
Myelodysplastic syndromes0.24 (0.22 to 0.27)0.81 (0.76 to 0.87)1.37 (1.22 to 1.52)1.39 (1.25 to 1.53)
Non-Hodgkin’s lymphoma1.29 (1.22 to 1.37)0.23 (0.22 to 0.25)1.19 (1.10 to 1.30)1.22 (1.13 to 1.32)
  • *ORs were calculated by the mean of logistic regression models adjusted for sex, age, number of Charlson comorbidities and category of hospital were death occurred. Acute leukaemia was chosen as the reference category.